Evaluating Endometriosis With 16α-(18)F-fluoro-17β-estradiol ([F-18] FES) PET/MRI

NCT04347135 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2024-05-10

No results posted yet for this study

Summary

Researchers are trying to improve the detection of endometriosis using F-18 FES PET/MRI imaging.

Conditions

  • Endometriosis

Interventions

DRUG

F-18 FES

F-18 FES PET/MRI for detection of endometriosis.

Sponsors & Collaborators

  • Annie (Annie) T. Packard

    lead OTHER

Principal Investigators

  • Ann Packard, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-07
Primary Completion
2024-04-30
Completion
2024-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04347135 on ClinicalTrials.gov